Focus: Kardigan is a Series B cardiovascular biotech focused on small-molecule therapeutics for heart disease, headquartered in South San Francisco. The company is advancing a pipeline of 3 clinical-stage programs targeting hypertension, cardiomyopathy, and aortic valve stenosis.
Profile data last refreshed 13h ago · AI intelligence enriched 1w ago
Stable — net -3 jobs in 30d
11 added, 14 removed. Backfill posture.
Best fit for clinical development and medical affairs professionals betting on a cardiology-focused IPO exit; higher risk for those seeking established infrastructure or near-term revenue stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Kardigan
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Kardigan's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Kardigan pursues public listing to advance heart disease pipeline - FirstWord Pharma
Kardigan pursues public listing to advance heart disease pipeline FirstWord Pharma
Kardigan targets IPO to support cardiology pipeline progression - Pharmaceutical Technology
Kardigan targets IPO to support cardiology pipeline progression Pharmaceutical Technology
Heart drug developer Kardigan files IPO - Pharmaphorum
Heart drug developer Kardigan files IPO Pharmaphorum
Kardigan itching for IPO to fund late-stage cardio pipeline - Fierce Biotech
Kardigan itching for IPO to fund late-stage cardio pipeline Fierce Biotech
IPO Tracker 2026: Kardigan cozies up to public markets to support heart disease drugs - BioSpace
IPO Tracker 2026: Kardigan cozies up to public markets to support heart disease drugs BioSpace
'A bit of a surprise': Kardigan's repeat dosing of blood pressure drug has no benefit over single shot - Endpoints News
'A bit of a surprise': Kardigan's repeat dosing of blood pressure drug has no benefit over single shot Endpoints News
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo